Actively Recruiting
Comparing Nadofaragene Firadenovec to Standard Treatments for Non-Muscle Invasive Bladder Cancer in a Randomized Trial
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-20
125
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing the effectiveness of different FDA-approved and NCCN-recommended drug treatments for non-muscle invasive bladder cancer NMIBC, focusing particularly on the FDA-approved drug nadofaragene firadenovec versus other standard treatments such as gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab. This phase 3 trial aims to evaluate which treatment offers better outcomes for patients with high-grade NMIBC who have had BCG failure. Participants will be randomly assigned to receive either nadofaragene firadenovec, administered as a saline solution instilled directly into the bladder every 3 months for up to 12 months, or best usual care, which often involves a combination of intravesical gemcitabine and docetaxel given weekly for 6 weeks, followed by monthly maintenance treatments for up to 24 months. This parallel study design compares these treatment approaches directly to assess their impact on disease progression. Throughout the study, participants will be monitored for up to 24 months to measure outcomes such as high-grade recurrence-free survival and progression-free survival. Regular clinical assessments include treatment administration visits, evaluations for disease recurrence or progression, and safety monitoring. The trial is designed to provide detailed information on how each treatment affects the course of NMIBC, helping to guide future care decisions.
CONDITIONS
Brief Title
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Research Team
E
Eugene Pietzak, MD
B
Bernard Bochner, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here